Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients. A significant proportion of patients had lopinavir, atazanavir and nevirapine trough concentrations exceeding the upper therapeutic threshold. Further studies are needed to identify good candidates/drugs for TDM, eventually allowing the selection of patients who may benefit from TDM-driven adjustments in antiretrovirals dosage.
Dario
D
Cattaneo
Sara
S
Baldelli
Simone
S
Castoldi
Nitin
N
Charbe
Valeria
V
Cozzi
Serena
S
Fucile
Emilio
E
Clementi
D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000069446:Atazanavir Sulfate; D016903:Drug Monitoring; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage / Q000493:pharmacokinetics; D019829:Nevirapine / Q000008:administration & dosage / Q000493:pharmacokinetics; D009842:Oligopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics; D010949:Plasma / Q000737:chemistry*; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics; D012189:Retrospective Studies
D044966:Anti-Retroviral Agents; D009842:Oligopeptides; D011725:Pyridines; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D019829:Nevirapine